Male Hypogonadism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Male Hypogonadism Market Outlook

Thelansis’s “Male Hypogonadism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Male Hypogonadism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Male Hypogonadism Overview

Hypogonadism refers to the diminished functional activity of the gonads, which are responsible for producing hormones (such as testosterone, estradiol, antimullerian hormone, progesterone, inhibin B, activin) and gametes (eggs or sperm). Male hypogonadism pertains explicitly to a deficiency in testosterone, a vital hormone for sexual, cognitive, and physiological development and functioning. Clinically low testosterone levels can result in the absence of secondary sexual characteristics, infertility, muscle wasting, and other abnormalities. Reduced testosterone levels may stem from abnormalities in the testicles, hypothalamus, or pituitary gland. There are two primary types of hypogonadism:

1. Primary hypogonadism: Also known as primary testicular failure, this type arises from issues within the testicles. Common causes include Klinefelter's syndrome, which involves an abnormality in the sex chromosomes (X and Y), where males typically possess one X and one Y chromosome. Klinefelter's syndrome has two or more X chromosomes and one Y chromosome.
2. Secondary hypogonadism: This form of hypogonadism indicates dysfunction in the hypothalamus or pituitary gland, which are components of the brain that signal the testicles to produce testosterone.

Hypogonadism is characterized by serum testosterone levels below 300 ng/dL in conjunction with at least one clinical sign or symptom. Signs of hypogonadism include the absence or regression of secondary sexual characteristics, anemia, reduced bone mass or bone mineral density, oligospermia, muscle wasting, and abdominal adiposity. Symptoms of post-pubescent hypogonadism comprise sexual dysfunction (such as erectile dysfunction, diminished libido, reduced penile sensation, difficulty achieving orgasm, and decreased ejaculate), decreased energy and stamina, depressed mood, heightened irritability, difficulties in concentration, alterations in cholesterol levels, anemia, osteoporosis, and hot flushes. The primary treatment option for hypogonadism is testosterone replacement therapy.

• The overall annual incidence of male hypogonadism is estimated to be 16.1 cases per 100,000 person-years, with the highest incidence observed among men aged 35-44 years, at 21.5 cases per 100,000 person-years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: